Magazine article Drug Topics

Industry Sees Economic Study as Road to Regulatory Help

Magazine article Drug Topics

Industry Sees Economic Study as Road to Regulatory Help

Article excerpt

What is the economic impact of drugs on diseases? Eli Lilly Co. has commissioned a study to find out, and the company hopes the results can help convince policy makers to assure a regulatory climate that will enable the industry to create "decisive technologies" that attack the underlying causes of illnesses.

Sidney Taurel, Lilly's president and chief operating officer, disclosed that the study was under way in a speech at the Pharmaceutical Research & Manufacturers of America in Boca Raton, Fla., last month. He succeeded Charles Heimbold of Bristol-Myers Squibb as PhRMA chairman.

Taurel said the National Bureau of Economic Research would evaluate the impact of prescription drugs in three major disease categories: cardiovascular diseases, depression, and infectious diseases. NBER, a network of university economists, is creating a price index for the treatment of acute myocardial infarction. Preliminary results, he noted, confirm that costs associated with AMI have fallen sharply in the past decade; shortterm and long-term mortality has been reduced, and pharmaceuticals have contributed significantly to those results. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.